Wang Xue-Ling, Schnoor Michael, Yin Lei-Miao
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China.
Department of Molecular Biomedicine, Center for Investigation and Advanced Studies of the National Polytechnic Institute (Cinvestav-IPN), Avenida IPN 2508, 07360 Mexico City, Mexico.
Pharmacol Ther. 2023 Apr;244:108374. doi: 10.1016/j.pharmthera.2023.108374. Epub 2023 Mar 6.
Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers.
金属硫蛋白-2（MT-2）最初被发现是锌稳态和镉解毒的介质。然而，MT-2最近受到了越来越多的关注，因为MT-2表达的改变与哮喘和癌症等多种疾病密切相关。已经开发了几种药理学策略来抑制或修饰MT-2，揭示了其作为疾病药物靶点的潜力。因此，有必要更好地了解MT-2的作用机制，以改进潜在临床应用的药物开发。在这篇综述中，我们重点介绍了在确定MT-2在炎症性疾病和癌症中的蛋白质结构、调节、结合伴侣和新功能方面的最新进展。
